LWA
BMRN icon

Lineweaver Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lineweaver Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,339
Closed -$289K – 182
2025
Q3 		$289K Buy
+5,339
New +$305K 0.04% 148

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Lineweaver Wealth Advisors's BMRN Position: Q4 2025 in Review

Lineweaver Wealth Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 5,339 shares — an estimated $289K sold.

Lineweaver Wealth Advisors first reported a position in BMRN in Q3 2025 and held it in 1 quarter. The position peaked at $289K in Q3 2025. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • Lineweaver Wealth Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Lineweaver Wealth Advisors sold 5,339 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $289K.
  • Lineweaver Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Lineweaver Wealth Advisors's BioMarin Pharmaceuticals position peaked at $289K in Q3 2025.
  • 539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Lineweaver Wealth Advisors's 13F filing for Q4 2025, filed 14 Jan 2026.